NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced that it entered into an agreement to supply TPOXX (tecovirimat) in Morocco. The contract was executed in response to a request from the Ministry of Health in Morocco to make the therapy available in the country and help prepare and protect its citizens against any potential mpox outbreak. Tecovirimat is approved in the U.S., C ...

Siga Technologies Inc. (SIGA) ended the recent trading session at $6.99, demonstrating a +0.36% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.9%. Meanwhile, the Dow gained 0.81%, and the Nasdaq, a tech-heavy index, added 1.22%. The company's stock has dropped by 12.67% in the past month, falling short of the Medical sector's loss of 4.05% and the S&P 500's gain of 3.15%. Investors will be eagerly watching for the performance of Siga Technolog ...

Core Viewpoint - SIGA Technologies is facing scrutiny over its disclosures regarding the potential expansion of its lead product, TPOXX®, for treating Mpox, following significant stock price declines and an investigation into possible securities law violations [1][6]. Group 1: Company Developments - SIGA initiated clinical trials in October 2022 to assess TPOXX®'s safety and efficacy for Mpox treatment in the Democratic Republic of Congo [2]. - On August 15, 2024, the National Institute of Allergy and Infectious Diseases (NIAID) announced that the clinical trial for TPOXX® failed to meet its primary endpoint, resulting in a nearly 20% drop in SIGA's stock price [3]. - SIGA terminated its Chief Medical Officer, Dr. Jay Varma, on September 23, 2024, without providing an explanation, which further impacted the company's stock price [4]. Group 2: Controversial Statements - A video surfaced on September 25, allegedly featuring Dr. Varma discussing the need to maintain public belief in TPOXX®'s efficacy and suggesting media manipulation to prevent stock devaluation, which led to another significant drop in SIGA's share price [5]. Group 3: Legal and Financial Implications - Hagens Berman has launched an investigation into SIGA Technologies for potential misleading statements regarding TPOXX®'s efficacy and commercial prospects, indicating possible violations of U.S. securities laws [6].

NEW YORK, Sept. 26, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating potential securities claims on behalf of purchasers of SIGA Technologies, Inc.(NASDAQ: SIGA) ("SIGA" or the "Company") SIGA Technologies, Inc. operates as a commercial-stage pharmaceutical company. The Company offers oral formulation of an antiviral drug for the treatment of human smallpox disease caused by vario ...

Siga Technologies Inc. (SIGA) ended the recent trading session at $8.43, demonstrating no swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.28%. Meanwhile, the Dow gained 0.15%, and the Nasdaq, a tech-heavy index, added 0.15%. Prior to today's trading, shares of the company had lost 11.17% over the past month. This has lagged the Medical sector's gain of 0.38% and the S&P 500's gain of 2% in that time. The investment community will be paying close attention to th ...

Group 1 - Siga Technologies Inc. closed at $7.88, reflecting a -1.38% change from the previous day, underperforming the S&P 500's daily gain of 0.03% [1] - Over the past month, Siga's shares have decreased by 23.47%, while the Medical sector gained 2.67% and the S&P 500 increased by 1.54% [1] - The upcoming financial results are anticipated, with analysts expecting earnings of $1.01 per share and revenue of $160.46 million, representing increases of +6.32% and +14.68% year-over-year, respectively [2] Group 2 - Recent changes to analyst estimates for Siga Technologies Inc. are being monitored, as upward revisions indicate positive sentiment regarding the company's business operations and profit generation capabilities [3] - The Zacks Rank system, which evaluates estimate changes, currently ranks Siga Technologies Inc. at 3 (Hold), with a steady consensus EPS estimate over the past month [5] - The company has a Forward P/E ratio of 7.91, indicating a discount compared to its industry's Forward P/E of 15.35, suggesting potential valuation attractiveness [6] Group 3 - The Medical - Drugs industry, which includes Siga Technologies Inc., holds a Zacks Industry Rank of 72, placing it in the top 29% of over 250 industries [6] - The Zacks Industry Rank assesses the strength of industry groups based on the average Zacks Rank of individual stocks, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [7]

The latest trading session saw Siga Technologies Inc. (SIGA) ending at $7.51, denoting a -0.53% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily gain of 1.07%. Elsewhere, the Dow gained 0.31%, while the tech-heavy Nasdaq added 2.17%. Heading into today, shares of the company had lost 19.94% over the past month, lagging the Medical sector's gain of 3.34% and the S&P 500's gain of 2.92% in that time. Analysts and investors alike will be keeping a close eye on the pe ...

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced a new contract with the U.S. Department of Defense (DOD) for the procurement of approximately $9 million of TPOXX® (Contract number: W911SR24C0030). This award is comprised primarily of oral TPOXX®, with a small amount of intravenous (IV) TPOXX®, and represents the third procurement contract award from the DOD over the past th ...

So-called "bull traps" often frustrate traders, as they did on Wednesday, snaring shares of SIGA Technologies Inc SIGA — and there may be another one today. That's why it's our 'Stock of the Day'. SIGA shares have been very active because of a surge in Mpox (The World Health Organization ceased using the term Monkey Pox in November 2022 to reduce the stigma and association with monkeys). SIGA produces treatments for this disease. The New York-based company released disappointing trial data for a drug to tre ...

Preliminary analysis shows the study did not reach statistical significance on its primary endpoint of tecovirimat being superior to placebo in lesion resolution for all patients Results suggest tecovirimat provides clinical benefit vs. placebo in two important patient populations: those treated early and those with severe disease Results affirm tecovirimat's strong safety profile Multiple additional clinical trials evaluating tecovirimat for mpox continue NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The Nat ...